相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia An Evolving Treatment Landscape
Curtis Lachowiez et al.
CANCER JOURNAL (2022)
Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation
Xi Jin et al.
DISEASE MODELS & MECHANISMS (2022)
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Feng Wang et al.
NATURE COMMUNICATIONS (2021)
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies
Yue Chen et al.
DRUG METABOLISM AND DISPOSITION (2021)
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Sung Choe et al.
BLOOD ADVANCES (2020)
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
Bettina Wingelhofer et al.
LEUKEMIA (2018)
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Lynn Quek et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M. Intlekofer et al.
NATURE (2018)
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen et al.
CANCER DISCOVERY (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael D. Amatangelo et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Konstantinos Tzelepis et al.
CELL REPORTS (2016)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Wei Li et al.
GENOME BIOLOGY (2014)
β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis
Thomas Oellerich et al.
BLOOD (2013)
In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling
Peter G. Miller et al.
CANCER CELL (2013)
Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness
Qing Li et al.
NATURE (2013)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Julie-Aurore Losman et al.
SCIENCE (2013)
Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma
Sina Haftchenary et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Masato Sasaki et al.
NATURE (2012)
A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells
Liang Li et al.
BLOOD (2011)
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
Erik A. Nelson et al.
BLOOD (2011)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation
Jasmin Batliner et al.
MOLECULAR IMMUNOLOGY (2011)
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice
George S. Vassiliou et al.
NATURE GENETICS (2011)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis
Barbara Joyce-Shaikh et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Proteomic and Genetic Approaches Identify Syk as an AML Target
Cynthia K. Hahn et al.
CANCER CELL (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Discovery of chromone-based inhibitors of the transcription factor STAT5
Judith Mueller et al.
CHEMBIOCHEM (2008)
Signal transduction pathways that contribute to myeloid differentiation
M. B. Miranda et al.
LEUKEMIA (2007)
Activation mechanisms of STAT5 by oncogenic Flt3-ITD
Chunaram Choudhary et al.
BLOOD (2007)
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
M Mizuki et al.
BLOOD (2000)
分享论文
